During the second washout phase, after treatment with the COC, one woman in Mizoribine treatment sequence B became pregnant and discontinued the study. The remaining 28 women started treatment period 2, which was completed by a total of 26 subjects: 13 subjects (86.7 %) in treatment sequence A and 13 subjects (92.9 %) in treatment sequence B. Two subjects discontinued this period prematurely: one was lost to follow-up, and the other discontinued following a protocol

deviation. Fig. 2 Disposition of subjects. a Subjects using the novel Bayer patch were regarded as having completed treatment if there were ≥77 days between “Last day patch removed” and “First day patch worn” in period 2; b The study was completed only if the subject 4SC-202 molecular weight had completed the treatment period and had performed the follow-up visit. COC combined oral contraceptive The key demographic characteristics of the FAS population are summarized in Table 1. Overall, characteristics were very similar between the treatment groups. Table 1 Subject demographics and baseline characteristics (full analysis set) for treatment sequence A (n = 15), treatment sequence B (n = 14), and in total (n = 29)   Treatment sequence Aa Treatment sequence Bb Total Characteristic [mean ± SD

(range)]  Age (years) 26.9 ± 5.3 (18–35) 27.2 ± 3.8 (18–32) 27.0 ± 4.6 (18–35)  Height (cm) 167.3 ± 4.5 (161–174) 166.8 ± 7.2 (148–178) 167.1 ± 5.8 (148–178)  Body weight (kg) 62.6 ± 7.0 (51–78) 62.5 ± 9.0 (44–78) 62.6 ± 7.9 (44–78)  BMI (kg/m2) 22.4 ± 2.4 (19–26) 22.4 ± 2.8 (19–29) 22.4 ± 2.6 (19–29) Race [n (%)]  Caucasian 14 (93.3) 13 (92.9) 27 (93.1)  Asian 1 (6.7) 1 (7.1) 2 (6.9) BMI body mass index, COC combined oral contraceptive, EE ethinyl estradiol, GSD gestodene, LNG levonorgestrel, SD standard deviation aTreatment sequence A = transdermal patch containing 0.55 mg EE and 2.1 mg GSD in period 1, COC containing 0.03 mg EE and 0.15 mg LNG in period 2 bTreatment sequence B = COC containing 0.03 mg EE and 0.15

mg LNG in period 1, transdermal patch containing 0.55 mg EE and 2.1 mg GSD in period 2 3.2 Primary Hemostasis Parameters With regard to prothrombin fragments 1 + 2, no statistically significant differences were observed between the treatment groups in either treatment period. While little change was observed in the first treatment period, an increase of prothrombin fragments 1 + 2 was seen in the second Montelukast Sodium treatment period for both groups (baseline values 0.099 and 0.109 nmol/L in the novel Bayer patch and COC groups, respectively; absolute changes 0.025 and 0.028 nmol/L in the novel Bayer patch and COC groups, respectively). Over both treatment periods, the overall mean absolute change was 0.008 ± 0.042 nmol/L for the novel Bayer patch group and 0.013 ± 0.043 nmol/L for the COC group; the treatment difference of 0 (two-sided 97.5 % CI −0.032 to 0.022) was not statistically significant (p = 0.667). There were no statistically significant treatment sequence or period effects.